Phaseline

Companies › Laboratorio Elea Phoenix

Laboratorio Elea Phoenix: clinical trials, targets and expected readouts

2 active drug programs in 79 registered trials: 48 Phase 2, 19 Phase 1, 11 Phase 3, 1 Phase 4; Infectious disease, Neurology, Genitourinary, Hematology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Benznidazole (2 weeks)
Antiparasitic agent active against Trypanosoma cruzi
–Phase 3Chagas DiseaseDec 2026
Cannabidiol
Cannabinoid CB1 receptor negative allosteric modulator
CNR1Phase 2Parkinson Disease; Phobia, Social; Acute Radicular Back Pain; Early Psychosis …Nov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05742724CannabidiolPhase 1CannabisGenitourinaryFeb 2024
NCT05092191CannabidiolPhase 2Multiple SclerosisNeurologyApr 2025
NCT04517799CannabidiolPhase 2AutismPsychiatryAug 2025
NCT06574100CannabidiolPhase 1PharmacokineticsOtherNov 2025
NCT04105231CannabidiolPhase 2Dual DiagnosisPsychiatryNov 2025
NCT04816994CannabidiolPhase 3Acute Radicular Back PainOtherDec 2025
NCT04550377CannabidiolPhase 2Post Traumatic Stress DisorderNeurologyMar 2026
NCT05860699CannabidiolPhase 2Severe Alcohol Use Disorder (DSM 5)PsychiatryMay 2026
NCT07570472CannabidiolPhase 2Sleep QualityOtherMay 2026
NCT07498023CannabidiolPhase 1FibromyalgiaOtherJul 2026
NCT06629389CannabidiolPhase 2Parkinson DiseaseNeurologyNov 2026
NCT06629389CannabidiolPhase 2Parkinson DiseaseNeurologyNov 2026
NCT06629389CannabidiolPhase 2Parkinson DiseaseNeurologyNov 2026
NCT03984565CannabidiolPhase 2Chronic PainOtherNov 2026
NCT04897516Benznidazole (2 weeks)Phase 3Chagas DiseaseInfectious diseaseDec 2026
NCT04897516Benznidazole (2 weeks)Phase 3Chagas DiseaseInfectious diseaseDec 2026
NCT04897516Benznidazole (2 weeks)Phase 3Chagas DiseaseInfectious diseaseDec 2026
NCT05803434CannabidiolPhase 2EpilepsyNeurologyDec 2026
NCT04411225CannabidiolPhase 3Early PsychosisPsychiatryDec 2026
NCT06477406CannabidiolPhase 2EndometriosisGenitourinaryDec 2026
NCT05457465CannabidiolPhase 2Bipolar DisorderPsychiatryDec 2026
NCT06014424CannabidiolPhase 2Alzheimer DiseaseNeurologyDec 2026
NCT06381791CannabidiolPhase 1Shoulder OsteoarthritisImmunologyDec 2026
NCT05969314CannabidiolPhase 1Breast CancerOncologyDec 2026
NCT06218056CannabidiolPhase 2Tobacco Use DisorderPsychiatryDec 2026
NCT06672666CannabidiolPhase 2AnxietyPsychiatryDec 2026
NCT06099379CannabidiolPhase 1CannabisPsychiatryDec 2026
NCT06099379CannabidiolPhase 1CannabisPsychiatryDec 2026
NCT07298408CannabidiolPhase 1Diabetic Peripheral Neuropathic Pain (DPN)NeurologyDec 2026
NCT06414473CannabidiolPhase 1Osteoarthritis, KneeImmunologyDec 2026
NCT06512389CannabidiolPhase 2Alcohol Use DisorderPsychiatryJan 2027
NCT06930703CannabidiolPhase 1Sickle Cell DiseaseHematologyFeb 2027
NCT04992624CannabidiolPhase 2Osteoarthritis, KneeImmunologyMar 2027
NCT05613608CannabidiolPhase 2Alcohol Use DisorderPsychiatryApr 2027
NCT06333041CannabidiolPhase 2Sanfilippo SyndromeMetabolic and endocrineApr 2027
NCT05649059CannabidiolPhase 4Phobia, SocialPsychiatryMay 2027
NCT06946940CannabidiolPhase 2FibromyalgiaOtherMay 2027
NCT06448923CannabidiolPhase 2FractureImmunologyJun 2027
NCT05067387CannabidiolPhase 1Drug AbusePsychiatryJun 2027
NCT06859723CannabidiolPhase 1Abuse CannabisPsychiatryJul 2027
NCT06859723CannabidiolPhase 1Abuse CannabisPsychiatryJul 2027
NCT06940674CannabidiolPhase 3Opioid Use Disorder (OUD)PsychiatryJul 2027
NCT05269628CannabidiolPhase 2Multiple SclerosisNeurologyAug 2027
NCT07123467CannabidiolPhase 3Generalized Anxiety Disorder (GAD)PsychiatryAug 2027
NCT05020028CannabidiolPhase 2Knee ArthritisImmunologySep 2027
NCT05629702CannabidiolPhase 2GlioblastomaOncologyOct 2027
NCT05514899CannabidiolPhase 2HIVInfectious diseaseOct 2027
NCT07668856CannabidiolPhase 3Refractory Epilepsy in ChildrenNeurologyNov 2027
NCT04482244CannabidiolPhase 2Advanced Breast CancerOncologyDec 2027
NCT07245238CannabidiolPhase 3MediciineImmunologyDec 2027
NCT02926859CannabidiolPhase 2SchizophreniaPsychiatryDec 2027
NCT06731894CannabidiolPhase 2Breast CarcinomaOncologyJan 2028
NCT06778564CannabidiolPhase 3PsychosisPsychiatryFeb 2028
NCT06137365CannabidiolPhase 2ObesityMetabolic and endocrineMar 2028
NCT06107062CannabidiolPhase 2Cannabis Use DisorderPsychiatryMar 2028
NCT06107062CannabidiolPhase 2Cannabis Use DisorderPsychiatryMar 2028
NCT06845124CannabidiolPhase 2Alcohol AddictionPsychiatryApr 2028
NCT05822362CannabidiolPhase 2Mild Cognitive ImpairmentNeurologyApr 2028
NCT06840899CannabidiolPhase 2Supra-sacral Spinal Cord InjuryNeurologyMay 2028
NCT06266611CannabidiolPhase 2SleepPsychiatryMay 2028

The 60 nearest readouts of 79 trials; the rest in the app.

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

CNR1 (1)

Companies with the same targets

Jazz Pharmaceuticals IGC Pharma Sinfatin Zynerba Pharmaceuticals Skye Bioscience PleoPharma Bazelet Nehushtan Incannex Healthcare Vertanical Alasht Pharmed

Companies built like this

Zynerba Pharmaceuticals NeuroTherapia Vertanical Bazelet Nehushtan IGC Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.